What is CTSO's market cap?

$14.37M, based on the Nov 4 close of $4.56.

Does Cytosorbents pay a dividend?

No regular cash dividend has been paid in the last year.

How much of CTSO is sold short?

114.4K shares, 0.2% of float, as of Oct 15, 2026.

What sector is CTSO in?

Healthcare, in the Surgical Instruments industry.

NASDAQ · CTSOHealthcareSurgical Instruments

Cytosorbents Corp. (CTSO)

$4.56+0.44%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$4.56▼ 71.18% in range

Nov 4, 2025Low $3.06 · High $140.04Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Cytosorbents closed at $4.56 on Nov 4, up 0.44%, 96.7% below its 52-week closing high. Volume of 11.3K shares was 0.15× its 20-day average (below normal).

Split-adjusted performance: +15.2% over one month, -60.0% over six months, -70.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $9.63M, up 0.2% from a year earlier, with a net margin of -45.9%.

Short interest was 114.4K shares at the Oct 15 settlement, down 7.7% from the prior report (0.2% of float, 10.3 days to cover).

Market cap$14.4M3.2M shares

Revenue · quarter$9.6M+0.2% YoY

Diluted EPS$-1.40−333.3% YoY

P/E · TTM—P/S 0.4×

Net margin-45.9%Gross 73.2%

Dividend yieldNone

52-week range3.06 – 140.04−96.7% from high

Volume11.3K0.15× 20-day avg

Volatility · 60d881.4%Annualised

Short % of float0.2%10.3 days to cover

Net cash-$12.8MCash $4.4M

Next earnings—Not scheduled

Split-adjusted performance

1W −13.0%1M +15.2%3M −42.8%6M −60.0%YTD −64.3%1Y −70.8%3Y −84.3%5Y −96.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 110 companies (100 = best)

6-month momentum17

Revenue growth22

Net margin32

Value (low P/E)—

Size20

Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.

Short interest

Details →

Shares short114.4K−7.7% vs prior

Days to cover10.3Settled Oct 15

% of float0.2%

Short vol. 10d35.0%of daily volume

Closest peers by size in Surgical Instruments

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
CTSOCytosorbents	$4.56	+0.44%	−60.0%	+0.2%	−45.9%	—	$14.4M
PAVMPAVmed	$1.66	−8.79%	−76.3%	+450.0%	−16603.0%	—	$13.3M	Compare
MODDModular Medical	$1.67	−5.65%	−57.3%	—	—	—	$15.9M	Compare
GUTSFractyl Health	$0.9725	+8.27%	−89.0%	—	—	—	$12.9M	Compare
SINTSiNtx Technologies	$1.66	−3.49%	−30.8%	+199.3%	−803.5%	—	$12.5M	Compare
PMIPicard Medical	$7.19	−7.58%	−38.0%	—	−191.6%	—	$16.8M	Compare
RVPRetractable Technologies	$0.5660	+0.71%	−18.3%	−31.1%	38.5%	—	$16.9M	Compare
FEMYFemasys	$1.44	+2.86%	−84.1%	−18.9%	−1346.8%	—	$12.1M	Compare
ARAYAccuray Incorporated	$0.1491	+3.97%	−68.7%	−20.9%	−1.9%	—	$17.8M	Compare

News about Cytosorbents

All news →

No recent articles focused on Cytosorbents.

Quick answers

What does Cytosorbents do?: CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
What is CTSO's market cap?: $14.37M, based on the Nov 4 close of $4.56.
Does Cytosorbents pay a dividend?: No regular cash dividend has been paid in the last year.
How much of CTSO is sold short?: 114.4K shares, 0.2% of float, as of Oct 15, 2026.
What sector is CTSO in?: Healthcare, in the Surgical Instruments industry.

About Cytosorbents

CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.

HQ: Princeton, NJ129 employeesListed May 17, 2005cytosorbents.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology